Y. Bautista

1.4k total citations
6 papers, 181 citations indexed

About

Y. Bautista is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Biotechnology. According to data from OpenAlex, Y. Bautista has authored 6 papers receiving a total of 181 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pulmonary and Respiratory Medicine, 3 papers in Oncology and 2 papers in Biotechnology. Recurrent topics in Y. Bautista's work include Occupational and environmental lung diseases (4 papers), Cancer Immunotherapy and Biomarkers (3 papers) and Pleural and Pulmonary Diseases (3 papers). Y. Bautista is often cited by papers focused on Occupational and environmental lung diseases (4 papers), Cancer Immunotherapy and Biomarkers (3 papers) and Pleural and Pulmonary Diseases (3 papers). Y. Bautista collaborates with scholars based in Mexico, United States and France. Y. Bautista's co-authors include Feliciano Barrón, Óscar Arrieta, Andrés F. Cardona, Zyanya Lucía Zatarain-Barrón, Marco Polo Peralta Álvarez, Christian Rolfo, Rafael Rosell, Scott Antonia, Anne S. Tsao and Dariusz M. Kowalski and has published in prestigious journals such as Annals of Oncology, Journal of Thoracic Oncology and JAMA Oncology.

In The Last Decade

Y. Bautista

6 papers receiving 179 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Y. Bautista Mexico 5 136 120 23 15 12 6 181
Praveen Aanur United States 5 56 0.4× 91 0.8× 58 2.5× 11 0.7× 4 0.3× 10 138
Elodie Amour France 6 136 1.0× 77 0.6× 6 0.3× 6 0.4× 13 1.1× 14 160
Oladimeji Akinboro United States 5 101 0.7× 114 0.9× 14 0.6× 11 0.7× 18 1.5× 15 148
Nicola Trim United Kingdom 5 86 0.6× 83 0.7× 13 0.6× 39 2.6× 21 1.8× 8 151
Karim Amrane France 5 70 0.5× 105 0.9× 26 1.1× 19 1.3× 11 0.9× 18 133
Solange Peters United States 4 50 0.4× 64 0.5× 30 1.3× 52 3.5× 22 1.8× 7 142
Konstantin Penkov United States 5 116 0.9× 116 1.0× 10 0.4× 20 1.3× 15 1.3× 5 137
Tomoyuki Ishiguro Japan 6 40 0.3× 102 0.8× 48 2.1× 18 1.2× 13 1.1× 10 129
Dae Ho Lee South Korea 4 110 0.8× 171 1.4× 33 1.4× 10 0.7× 13 1.1× 6 182
Juan Carlos Vázquez Limón United States 7 75 0.6× 82 0.7× 45 2.0× 12 0.8× 8 0.7× 10 101

Countries citing papers authored by Y. Bautista

Since Specialization
Citations

This map shows the geographic impact of Y. Bautista's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Y. Bautista with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Y. Bautista more than expected).

Fields of papers citing papers by Y. Bautista

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Y. Bautista. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Y. Bautista. The network helps show where Y. Bautista may publish in the future.

Co-authorship network of co-authors of Y. Bautista

This figure shows the co-authorship network connecting the top 25 collaborators of Y. Bautista. A scholar is included among the top collaborators of Y. Bautista based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Y. Bautista. Y. Bautista is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

6 of 6 papers shown
1.
Scherpereel, Arnaud, Scott Antonia, Y. Bautista, et al.. (2022). First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743. Lung Cancer. 167. 8–16. 17 indexed citations
2.
3.
Baas, Paul, Arnaud Scherpereel, Anna K. Nowak, et al.. (2020). ID:2908 First-Line Nivolumab + Ipilimumab vs Chemotherapy in Unresectable Malignant Pleural Mesothelioma: CheckMate 743. Journal of Thoracic Oncology. 15(10). e42–e42. 37 indexed citations
4.
Arrieta, Óscar, Feliciano Barrón, Zyanya Lucía Zatarain-Barrón, et al.. (2020). Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non–Small Cell Lung Cancer. JAMA Oncology. 6(6). 856–856. 111 indexed citations
5.
6.
Brahmer, Julie R., Leora Horn, Suresh S. Ramalingam, et al.. (2019). O.02 Long-term Survival Outcomes with Nivolumab (NIVO) in Pts with Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC): Impact of Early Disease Control and Response. Journal of Thoracic Oncology. 14(11). S1152–S1153. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Praveen Aanur Breakdown of academic impact, for papers by Elodie Amour Breakdown of academic impact, for papers by Oladimeji Akinboro Breakdown of academic impact, for papers by Nicola Trim Breakdown of academic impact, for papers by Karim Amrane Breakdown of academic impact, for papers by Solange Peters Breakdown of academic impact, for papers by Konstantin Penkov Breakdown of academic impact, for papers by Tomoyuki Ishiguro Breakdown of academic impact, for papers by Dae Ho Lee Breakdown of academic impact, for papers by Juan Carlos Vázquez Limón
Rankless by CCL
2026